Drug intelligence / Profile preview

OPB-201

Development stage: Phase 1
Lead developer: Outpace Bio
Modality: TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

OPB-201 is an investigational TCR-T cell therapy developed by Outpace Bio for the treatment of solid tumors. As a T-cell receptor (TCR) engineered T-cell therapy, it involves modifying patient-derived T cells to express specific TCRs that recognize tumor-associated antigens, enabling targeted immune responses against cancer cells. The drug is currently in preclinical development and has not yet entered clinical trials or received regulatory approval. Its primary therapeutic area is neoplasms, with a focus on solid tumors.

Targets

pMHC (Peptide-MHC complex family)

Beyond the preview

Go deeper on OPB-201.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OPB-201.

Explore the full profile